Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00261950 · ClinicalTrials.gov registry record · Phase 2
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
A Phase 2 study of Secondary Hyperparathyroidism, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT00261950: Completed Phase 2 study of Secondary Hyperparathyroidism, sponsored by Amgen.
NCT00261950 is a Phase 2 study of Secondary Hyperparathyroidism that has completed, run by Amgen. The registered enrollment target is 110 participants, above the 51-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (116% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00261950, a Phase 2 study of Secondary Hyperparathyroidism, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
Conditions Studied
Interventions
- DRUG Sensipar (Cinacalcet HCl)
Study Locations (20)
New York
- Research Site - Flushing
- Research Site - Great Neck
- Research Site - New York
- Research Site - The Bronx
Other
- Research Site - Antwerp
- Research Site - Antwerp
- Research Site - Brussels
- Research Site - Leuven
Arizona
- Research Site - Phoenix
California
- Research Site - Los Angeles
Colorado
- Research Site - Denver
Connecticut
- Research Site - New Haven
Florida
- Research Site - Fort Lauderdale
Illinois
- Research Site - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
What the finished NCT00261950 record still lists
NCT00261950 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 51-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (116% higher).
The record links to 1 condition, with Secondary Hyperparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Sensipar (Cinacalcet HCl) is the first listed.
NCT00261950 names 20 study sites across 14 states, led by New York, Other, Arizona.
Frequently Asked Questions
What is clinical trial NCT00261950 about?
NCT00261950 is a clinical study titled "Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease". The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
What is the current status of trial NCT00261950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2006-05. Estimated completion is 2011-05.
What conditions does trial NCT00261950 study?
This clinical trial studies the following conditions: Secondary Hyperparathyroidism.
What interventions are being tested in trial NCT00261950?
The interventions under investigation include: Sensipar (Cinacalcet HCl) (DRUG).
Who is sponsoring clinical trial NCT00261950?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00261950 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00261950's enrollment target sits among peer trials
110 1st of 8 higher than 8 of 8 other Secondary Hyperparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Secondary Hyperparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
COMPLETED · Phase 2
-
Precision Medicine Approaches to Renal Osteodystrophy
RECRUITING
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
COMPLETED · Phase 4
-
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia